Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 04, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 2,270,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,101.16 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 9.08% of total voting rights).
- Shares in Issue: 5,332,618,601 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,270,000 shares. Consequently, the number of shares in issue was adjusted to 5,332,618,601. The filing does not provide comparative data against prior periods for operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It strictly serves as a notification of the share repurchase and cancellation in conformity with the Financial Services Authority's Disclosure and Transparency Rules. The document explicitly states it does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the updated share count of 5,332,618,601 for calculating ownership percentages under Disclosure and Transparency Rules.
- Confirm the total treasury holding of 484,194,158 shares (9.08% of voting rights) for capital structure analysis.
- Note that this filing does not contain operational performance data; refer to Form 20-F for full financial results.